Home > Healthcare > Pharmaceuticals > Finished Drug Form > Exocrine Pancreatic Insufficiency Treatment Market

Exocrine Pancreatic Insufficiency Treatment Market Trends

Report ID: GMI9379
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Exocrine Pancreatic Insufficiency Treatment Market Trends

The exocrine pancreatic insufficiency (EPI) treatment market is largely accelerated by the growing aging population base. The global demographic landscape is shifting toward an older population, increasing the prevalence of age-related health conditions, including those leading to EPI, and boosting the demand for pancreatic enzyme replacement therapy (PERT).
According to the World Health Organization (WHO), the global population aged 60 and over is projected to grow from 1 billion in 2020 to 1.4 billion by 2030, eventually doubling to 2.1 billion by 2050. Furthermore, the number of individuals aged 80 and older is expected to triple by 2050, reaching 426 million.
Therefore, this demographic trend highlights the increasing need for effective treatments that address age-related health conditions such as EPI, further propelling the growth of the PERT market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global exocrine pancreatic insufficiency treatment industry was valued at approximately USD 2.7 billion in 2023 and is estimated to grow at a 5.6% CAGR from 2024 to 2032, driven by increasing awareness and diagnosis rates.

The pancreatic enzyme replacement therapy (PERT) segment dominated the market with a revenue of USD 2.3 billion in 2023 and is expected to grow significantly over the forecast period due to its effectiveness in improving nutrient absorption and alleviating gastrointestinal issues.

North America exocrine pancreatic insufficiency treatment industry accounted for a 56.9% revenue share in 2023 and is projected to reach USD 2.4 billion by 2032, supported by advanced healthcare infrastructure and broad access to PERT.

Key players in the market include Abbott Laboratories, AbbVie, Digestive Care, Essential Pharma, Nestle, Nordmark Pharma, and Sun Pharmaceutical Industries.